Table 2 Brentuximab vedotin-based salvage regimens assessed in patients with R/R HL
Regimen(s) | Patients | Response before transplant | OS | PFS |
|---|---|---|---|---|
B + DHAP [48] | R/R HL (N = 61) | • Metabolic CR 79% • Metabolic PR 8% • Progressive disease 7% • 87% of pts. were mobilized and received ASCT | 2-year OS 92% | 2-year PFS 76% |
BrESHAP [49] | R/R HL after frontline chemotherapy (N = 66) | • ORR 91% • CR 82% • PR 10% • 64 pts. were mobilized and 60 received SCT | 30-month OS 91% | 30-month PFS 71% |
PET-adapted brentuximab vedotin + aICE [16] | R/R HL who had failed one previous doxorubicin regimen (N = 46) | • ~ 30% of pts. achieved PET-negativity with brentuximab vedotin alone • aICE increased PET-negativity rates to ~ 80% | NR | 2-year EFS = 82% |
First relapse or primary refractory CD30+ cHL (N = 24 [50]) (N = 42 [51]) | • 87% CR per investigator, 70% per independent review [50] • 69.2% CMR [51] | NR | 1-year PFS estimate 69% (95% CI 53–81%) | |
Brentuximab vedotin [52] | R/R HL (N = 37) | • Best ORR = 69% (CR = 33%) • 12 pts. with CR received SCT • 11/13 pts. with PR and all pts. with SD/PR required additional chemotherapy | NR | NR |
Brentuximab vedotin + bendamustine [53] | R/R HL (N = 55) | • ORR 92.5% • CR 73.6% • 41 patients were mobilized and 40 underwent ASCT | NR | 2-year PFS 62.6% |
Brentuximab vedotin + nivolumab [54] | R/R HL (N = 61) | • ORR 82% • CR 61% • 54 pts. underwent ASCT | NR | 6-month estimated PFS 89% |